Drugs / K8
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05699759 | Jan → Jun 2024 | diabetic macular edema | Michelle Abou-Jaoude | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06164587 | Apr 2024 → May 2026 | age-related macular degeneration, diffuse secondary choroid atrophy | Inflammasome Therapeutics | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | K8 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06164587 ↗ |
| Known as | Kamuvudine-8 | “A Non-randomized, Open Label, Safety and Efficacy Study Evaluating a Single Dose of Kamuvudine-8 (K8) for the Treatment of Patients with Diabetic Macular Edema” NCT05699759 ↗ |
| Route | Intravitreal | “administered intravitreally” NCT05699759 ↗ |